Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
Andrew Stevens
University of Birmingham
121Publications
30H-index
3,251Citations
Publications 121
Newest
Published on May 1, 2019in BMJ Open 2.38
Derek Ward8
Estimated H-index: 8
(University of Birmingham),
Lucy Doos6
Estimated H-index: 6
(University of Birmingham),
Andrew Stevens30
Estimated H-index: 30
(University of Birmingham)
Objectives To investigate the trend in the launch price of new drugs for five common health conditions. Design Cross-sectional study using data on new drugs launched in the UK between 1981 and 2015 for hypertension, asthma, rheumatoid arthritis, schizophrenia and colorectal cancer. Data and sources All drugs marketed in the UK between 1981 and 2015 (inclusive), and licensed specifically for the treatment of one of the five chosen conditions were included in the study. Newly launched medicines an...
Published on Dec 7, 2018
Tom Marshall27
Estimated H-index: 27
,
Sue Simpson13
Estimated H-index: 13
,
Andrew Stevens5
Estimated H-index: 5
Published on Jul 1, 2017in BMJ Open 2.38
Lucy Doos6
Estimated H-index: 6
(University of Birmingham),
Claire Packer11
Estimated H-index: 11
(University of Birmingham)
+ 2 AuthorsAndrew Stevens30
Estimated H-index: 30
(University of Birmingham)
Objective To describe and classify health technologies predicted in forecasting studies. Design and methods A portrait describing health technologies predicted in 15 forecasting studies published between 1986 and 2010 that were identified in a previous systematic review. Health technologies are classified according to their type, purpose and clinical use; relating these to the original purpose and timing of the forecasting studies. Data sources All health-related technologies predicted in 15 for...
Claire Packer11
Estimated H-index: 11
,
Derek Ward8
Estimated H-index: 8
+ 2 AuthorsLucy Doos6
Estimated H-index: 6
Lucy Doos6
Estimated H-index: 6
(University of Birmingham),
Derek Ward8
Estimated H-index: 8
(University of Birmingham)
+ 1 AuthorsClaire Packer11
Estimated H-index: 11
(University of Birmingham)
Objectives To determine the accuracy of pharmaceutical companies' predictions of drug licensing timeframes for their products in late stage clinical development. Methods We compared predicted licensing dates provided to the National Institute for Health Research Horizon Scanning Research and Intelligence Centre by pharmaceutical companies against actual marketing authorisation application (MAA) and marketing authorisation (MA) dates published by the European Medicines Agency for drugs granted au...
Published on May 1, 2016in BMJ Quality & Safety 7.04
Yen-Fu Chen22
Estimated H-index: 22
(Warw.: University of Warwick),
Karla Hemming5
Estimated H-index: 5
(University of Birmingham)
+ 1 AuthorsRichard Lilford66
Estimated H-index: 66
(Warw.: University of Warwick)
Evaluations of service delivery interventions with contemporaneous controls often yield null results, even when the intervention appeared promising in advance. There can be many reasons for null results. In this paper we introduce the concept of a ‘rising tide’ phenomenon being a possible explanation of null results. We note that evaluations of service delivery interventions often occur when awareness of the problems they intend to address is already heightened, and pressure to tackle them is mo...
Published on Mar 1, 2016in Lancet Oncology 35.39
Caroline J Hall2
Estimated H-index: 2
(National Institute for Health and Care Excellence),
Sally Doss3
Estimated H-index: 3
(National Institute for Health and Care Excellence)
+ 2 AuthorsAndrew Stevens30
Estimated H-index: 30
(National Institute for Health and Care Excellence)
Published on Mar 1, 2016in BMJ Open 2.38
Lucy Doos6
Estimated H-index: 6
(University of Birmingham),
Claire Packer11
Estimated H-index: 11
(University of Birmingham)
+ 2 AuthorsAndrew Stevens30
Estimated H-index: 30
(University of Birmingham)
Objectives Forecasting can support rational decision-making around the introduction and use of emerging health technologies and prevent investment in technologies that have limited long-term potential. However, forecasting methods need to be credible. We performed a systematic search to identify the methods used in forecasting studies to predict future health technologies within a 3–20-year timeframe. Identification and retrospective assessment of such methods potentially offer a route to more r...
Published on Dec 1, 2015
Jason Madan18
Estimated H-index: 18
(UoB: University of Bristol),
Tony Ades5
Estimated H-index: 5
(UoB: University of Bristol)
+ 9 AuthorsJonathan Tosh10
Estimated H-index: 10
(University of Sheffield)
Introduction Biologic therapies are efficacious but costly. A number of health economic models have been developed to determine the most cost-effective way of using them in the treatment pathway. These models have produced conflicting results, driven by differences in assumptions, model structure, and data, which undermine the credibility of funding decisions based on modeling studies. A Consensus Working Party met to discuss recommendations and approaches for future models of biologic therapies...
Published on Nov 16, 2015in BMJ Open 2.38
Derek Ward8
Estimated H-index: 8
(University of Birmingham),
Edward Hammond1
Estimated H-index: 1
(University of Birmingham)
+ 1 AuthorsAndrew Stevens30
Estimated H-index: 30
(University of Birmingham)
Objectives Recent decades have witnessed the development of highly innovative new antiviral drug therapies. However, there are concerns that rising costs and lengthening development times could have implications for future patient access to innovative new drugs. We sought to establish whether the time taken for the clinical development of new antiviral drugs launched in the UK had increased since the 1980s. Design and setting Retrospective observational study of all new antiviral drugs licensed ...
12345678910